Abstracts tagged "DMARDs"

Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
D. van der Heijde¹, Y. Tanaka², Roy Fleischmann³, Edward Keystone⁴, Joel M. Kremer⁵, C. Zerbini⁶, M. H. Cardiel⁷, S. B. Cohen⁸, P. T. Nash⁹, Y. Song¹⁰, D. Tegzova¹¹, B. Wyman¹², D. Gruben¹², B. Benda¹³, G. Wallenstein¹⁴, S. Krishnaswami¹², S. H. Zwillich¹², J. Bradley¹⁵, C. A. Connell¹⁶ and ORAL Scan Investigators¹⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵The Center for Rheumatology, Albany Medical College, Albany, NY, ⁶CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, ⁷Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁸Metroplex Clinical Research Centre, Dallas, TX, ⁹Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ¹⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Pfizer Inc., Groton, CT, ¹³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ¹⁴Pfizer Inc, New York, NY, ¹⁵Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ¹⁶Pfizer Inc, Groton, CT, ¹⁷Groton
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…
Abstract Number: 370 • 2012 ACR/ARHP Annual Meeting
Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima⁸, Yuichi Takahashi⁹, Seiyo Honda¹⁰, Yoshiro Horai², Tomohiro Koga¹, Ryu Watanabe¹¹, Hiroshi Okuno¹² and Katsumi Eguchi¹³, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Yu Family Clinic, Sendai, Japan, ¹⁰Kurume University School of Medicene, Kurume, Japan, ¹¹Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, ¹²Tohoku University Hospital, Sendai, Japan, ¹³Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the…
Abstract Number: 2172 • 2012 ACR/ARHP Annual Meeting
An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Susan Knowles¹, Dominick Sudano¹, Sara Taroumian², Neil M. Ampel³, John Galgiani⁴, Jeffrey R. Lisse¹ and Susan E. Hoover⁵, ¹Department of Rheumatology, University of Arizona, Tucson, AZ, ²Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³Infectious Disease, University of Arizona, Tucson, AZ, ⁴Valley Fever Center for Excellence, Tucson, AZ, ⁵Infectious Diseases, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease…
Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Kevin L. Winthrop¹, S.-H. Park², A. Gul³, M. Cardiel⁴, JJ Gomez-Reino⁵, D. Ponce de Leon⁶, R. Riese⁷, R. Chew⁷, T. Kawabata⁷, E. Mortensen⁶ and H. Valdez⁸, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²The Catholic University of Korea, Seoul, South Korea, ³Istanbul University, Istanbul, Turkey, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Pfizer Inc., Collegeville, PA, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., New York, NY
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
Abstract Number: 378 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Nicole M. Engel-Nitz¹, Sarika Ogale² and Mahesh Kulakodlu¹, ¹Observational Research, OptumInsight, Eden Prairie, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Studies have shown better response for anti-TNFs (aTNF) when they are used in combination with non-biologic DMARDs (nbDMARD), than when used as monotherapies.1 Therefore,…
Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
Jean-Marie Berthelot and Celine Cozic, Rheumatology Unit, Nantes University Hospital, Nantes, France
Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…
Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Jurgen Wollenhaupt¹, Joel C. Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Koshika Soma⁵, Lisy Wang⁴, Hiroyuki Nakamura⁶, Yoshihiro Komuro⁶, Chudi I. Nduaka⁴, David Gruben⁴, Birgitta Benda⁷, Samuel H. Zwillich⁵, Richard Riese⁴ and John D. Bradley⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Japan Inc., Tokyo, Japan, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
Abstract Number: 382 • 2012 ACR/ARHP Annual Meeting
Does Biased Risk Perception Explain the Underuse of Disease Modifying Anti-Rheumatic Drugs?
Richard W. Martin¹, Andrew J. Head², James D. Birmingham³ and Aaron T. Eggebeen¹, ¹Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ²Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ³Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: The prescription of a Disease Modifying Anti-rheumatic Drugs (DMARD) for patients with rheumatoid arthritis (RA) is considered a standard of effective care. However a…
Abstract Number: 2131 • 2012 ACR/ARHP Annual Meeting
An Evaluation of Prognostic Factors for Orthopaedic Joint Surgery in Rheumatoid Arthritis. Results From Two Multicentre UK Inception Cohorts (1986-2011)
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, David James⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young³, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, ⁴Rheumatology, Diana Princess of Wales Hospital, Grimsby, United Kingdom, ⁵Rheumatology Dept, St. Georges Hospital, London, United Kingdom, ⁶Academic Rheum/Clin Sci Bldg, City Hospital, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom
Background/Purpose: The need for orthopaedic surgery in Rheumatoid Arthritis (RA) is the result of failed medical treatment and a surrogate marker for joint destruction. Reliable…
Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Gerd Burmester¹, Désirée van der Heijde², Vibeke Strand³, Cristiano A. F. Zerbini⁴, Carol A. Connell⁵, Charles A. Mebus⁵, Samuel H. Zwillich⁶, John D. Bradley⁵, David Gruben⁵ and Gene Wallenstein⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
Abstract Number: 365 • 2012 ACR/ARHP Annual Meeting
Improvement of Health-Related Quality of Life in RA Patients Treated with Biologics – One-Year Follow-up Data of the German Biologics Register Rabbit
Kerstin Gerhold¹, Adrian Richter², Matthias Schneider³, Hans Joachim Bergerhausen⁴, Winfried Demary⁵, Anke Liebhaber⁶, Joachim Listing⁷, Angela Zink⁸ and Anja Strangfeld⁹, ¹Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Klinik für Rheumatologie, Wedau Kliniken - Klinikum Duisburg, Duisburg, Germany, ⁵Private Practice, Hildesheim, Germany, ⁶Private Practice, Halle, Germany, ⁷German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁸Epidemiology Unit, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany
Background/Purpose: Health‐related quality of life (HRQoL) has been increasingly recognized as a crucial indicator of disease burden in chronic diseases such as rheumatoid arthritis (RA).…
Abstract Number: 2140 • 2012 ACR/ARHP Annual Meeting
A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study
Paul Bird¹, David Nicholls², Julien P. de Jager³, Hedley Griffiths⁴, Lynden Roberts⁵, Kathleen Tymms⁶, Jane Zochling⁷, Mark H. Arnold⁸, Geoffrey O. Littlejohn⁹ and OPAL Consortium¹⁰, ¹Combined Rheumatology Practice, Sydney, Australia, ²Coast Joint Care, Maroochydore, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Barwon Rheumatology Service, Geelong, Australia, ⁵School of Medicine, James Cook University, Townsville, Australia, ⁶Canberra Rheumatology, Canberra, ACT, Australia, ⁷Menzies Research Institute Tasmania, Hobart, Australia, ⁸Orthopaedic Arthritis Spec Ctr, Level 2 The Gallery, Chatswood, Australia, ⁹Rheumatology, Monash Medical Center, Melbourne, Australia, ¹⁰Melbourne, Australia
Background/Purpose: Despite the conspicuous increase in available treatment for rheumatoid arthritis [RA], and the shift to early, more aggressive management, there is a paucity of…
Abstract Number: 1284 • 2012 ACR/ARHP Annual Meeting
Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
K. L. Winthrop¹, A. Racewicz², E. B. Lee³, B. Wilkinson⁴, S. H. Zwillich⁵, K. Soma⁴, S. Rottinghaus⁴, T. Kawabata⁴, R. Riese⁵, S. Wood⁵, J. Bradley⁶ and Clifton O. Bingham III⁷, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Department of Internal Medicine and Osteoarthrology, Bialystok Regional Hospital, Bialystok, Poland, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁷Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Clinical guidelines recommend the use…
Abstract Number: 342 • 2012 ACR/ARHP Annual Meeting
Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model
Shireen Vali¹, Canio Refino², Jay Dela Cruz², Robinson Vidva¹, Prashant Nair¹, Saumya Radhakrishnan¹, Pradeep Fernandes¹, Taher Abbasi¹ and Gurkirpal Singh³, ¹CellWorks Group, Saratoga, CA, ²InTouch Bio, Alameda, CA, ³Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves a complex interaction of multiple cell systems, cytokines and mediators. We recently developed a predictive software-based mathematical model that emulates…
Abstract Number: 1840 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Jeffrey R. Curtis¹, Genevieve Gauthier², Robert Hiscock² and Frank Zhang³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Analysis Group, Inc., Montreal, QC, Canada, ³Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). Oral disease modifying anti-rheumatic drugs (DMARDs) are often used as a first-line treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].